Clinical Trial Update: Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible [Phase 1, Phase 2]

View source ↗

Summary

This entry reports a Phase I/II clinical trial evaluating all-trans retinoic acid (ATRA) in combination with TCP in patients with relapsed or refractory acute m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• ATRA (all-trans retinoic acid)
• TCP

Snippet

Sponsor: Martin-Luther-Universität Halle-Wittenberg | Conditions: AML | Phase 1, Phase 2 | Status: UNKNOWN